NURIX THERAPEUTICS IN

Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical Sites

30 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) Congress

10 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)

03 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development

26 May 2022 07:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Dosing of First Patient in Phase 1 Clinical Trial of NX-5948, a Selective BTK Degrader, in Development for B-cell Leukemias and Lymphomas

17 May 2022 07:00:02 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference

11 May 2022 16:02:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Host R&D Day on May 26, 2022

09 May 2022 16:02:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting

08 Apr 2022 13:02:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update

07 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of DeTIL-0255, a Drug-Enhanced Cell Therapy for the Treatment of Patients with Solid Tumors

05 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

04 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607

29 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

09 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127) and CBL-B Inhibitor (NX-0255) Programs at the American Association for Cancer Research Annual Meeting

08 Mar 2022 16:47:52 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference

10 Feb 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update

27 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts

10 Jan 2022 07:00:03 By Nasdaq GlobeNewswire

Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 16:01:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

12 Dec 2021 09:00:00 By Nasdaq GlobeNewswire

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors

12 Nov 2021 07:09:00 By Nasdaq GlobeNewswire